Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial

European Journal of Cancer

Volumn 68, Issue , 2016, Pages 156-162

  Levy, Antonin ^a,b   Massard, Christophe ^a   Soria, Jean Charles ^a   Deutsch, Eric ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Anti PD L1; Immunoradiotherapy; Phase 1; Phase 2; Radiotherapy

Indexed keywords

DURVALUMAB; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EYE MELANOMA; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MUCOSA INFLAMMATION; ORGANS AT RISK; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION INJURY; RETREATMENT; RISK ASSESSMENT; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT DURATION; TREATMENT INTERRUPTION; TUMOR GROWTH; VERY ELDERLY; VOMITING; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CHEMORADIOTHERAPY; CLINICAL TRIAL; COLONIC NEOPLASMS; CONFORMAL RADIOTHERAPY; DISEASE FREE SURVIVAL; EYE NEOPLASMS; HEAD AND NECK NEOPLASMS; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MELANOMA; MIDDLE AGED; NEOPLASMS; PATHOLOGY; RADIOSURGERY; SECONDARY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CHEMORADIOTHERAPY; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; EYE NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; RADIOSURGERY; RADIOTHERAPY, CONFORMAL; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84994383071     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.09.013     Document Type: Article

References (29)

1. [1] Demaria, S., Golden, E.B., Formenti, S.C., Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1 (2015), 1325–1332.
2. [2] Levy, A., Chargari, C., Cheminant, M., Simon, N., Bourgier, C., Deutsch, E., Radiation therapy and immunotherapy: implications for a combined cancer treatment. Crit Rev Oncol Hematol 85 (2013), 278–287.
3. [3] Dovedi, S.J., Adlard, A.L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E.J., et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74 (2014), 5458–5468.
4. [4] Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R.R., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124 (2014), 687–695.
5. [5] Sharabi, A.B., Lim, M., DeWeese, T.L., Drake, C.G., Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16 (2015), e498–e509.
6. [6] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med, 372, 2015, 2521e32.
7. [7] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639 22.
8. [8] Massard, C., Gordon, M.S., Sharma, S., Rafii, S., Wainberg, Z.A., Luke, J., et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34 (2016), 3119–3125.
9. [9] Antonia, S.J., Kim, S.-W., Spira, A.I., Ahn, M.J., Ou, S.-H., Stjepanovic, N., et al. Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer. J Clin Oncol, 34, 2016 (suppl; abstr 9029).
10. [10] Rebelatto, M., Mistry, A., Sabalos, C., Walker, J., Midha, A., Steele, K., et al. Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients. J Clin Oncol, 33, 2015 (suppl; abstr 8033).
11. [11] Marks, L.B., Yorke, E.D., Jackson, A., Ten Haken, R.K., Constine, L.S., Eisbruch, A., et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76 (2010), S10–S19.
12. [12] Ferté, C., Fernandez, M., Hollebecque, A., Koscielny, S., Levy, A., Massard, C., et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res 20 (2014), 246–252.
13. [13] Levy, A., Hollebecque, A., Ferté, C., Koscielny, S., Fernandez, M., Soria, J.C., et al. Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol, 31, 2013, 395.
14. [14] Sagiv-Barfi, I., Rajapaksa, A., Czerwinski, D., Chang, S., Hebb, J., Chester, C., et al. Local tumour irradiation combined with α-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumour responses: successful translation of a mouse model to a human case series. Canc Res, 74S, 2014 (AACR 2014. Abstract nr 2941).
15. [15] Vanpouille-Box, C., Diamond, J.M., Pilones, K.A., Zavadil, J., Babb, J.S., Formenti, S.C., et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res 75 (2015), 2232–2242.
16. [16] Chiang, C.S., Fu, S.Y., Wang, S.C., Yu, C.F., Chen, F.H., Lin, C.M., et al. Irradiation promotes an M2 macrophage phenotype in tumour hypoxia. Front Oncol, 2, 2012, 89.
17. [17] Teresa Pinto, A., Laranjeiro Pinto, M., Patrícia Cardoso, A., Monteiro, C., Teixeira Pinto, M., Filipe Maia, A., et al. Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities. Sci Rep, 6, 2016, 18765.
18. [18] Park, S.S., Dong, H., Liu, X., Harrington, S.M., Krco, C.J., Grams, M.P., et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 3 (2015), 610–619.
19. [19] Liang, H., Deng, L., Chmura, S., Burnette, B., Liadis, N., Darga, T., et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol 190 (2013), 5874–5881.
20. [20] Zeng, J., See, A.P., Phallen, J., Jackson, C.M., Belcaid, Z., Ruzevick, J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86 (2013), 343–349.
21. [21] Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
22. [22] Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.
23. [23] Stamell, E.F., Wolchok, J.D., Gnjatic, S., Lee, N.Y., Brownell, I., The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 85 (2013), 293–295.
24. [24] Levy, A., Chargari, C., Marabelle, A., Perfettini, J.L., Magné, N., Deutsch, E., Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. Eur J Cancer 62 (2016), 36–45.
25. [25] Michot, J.M., Mazeron, R., Dercle, L., Ammari, S., Canova, C., Marabelle, A., et al. Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. Eur J Cancer 66 (2016), 91–94.
26. [26] Schaue, D., Ratikan, J.A., Iwamoto, K.S., McBride, W.H., Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83 (2012), 1306–1310.
27. [27] Dewan, M.Z., Galloway, A.E., Kawashima, N., Dewyngaert, J.K., Babb, J.S., Formenti, S.C., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15 (2009), 5379–5388.
28. [28] Monjazeb, A.M., Schoenfeld, J.D., Radiation dose and checkpoint blockade immunotherapy: unanswered questions. Lancet Oncol 17 (2016), e3–e4.
29. [29] Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.